Skip to main content

Research Repository

Advanced Search

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice

Gu, Yue; Avolio, Elisa; Alvino, Valeria V; Thomas, Anita C; Herman, Andrew; Miller, Poppy J; Sullivan, Niall; Faulkner, Ashton; Madeddu, Paolo

Authors

Yue Gu

Elisa Avolio

Valeria V Alvino

Anita C Thomas

Andrew Herman

Poppy J Miller

Niall Sullivan

Ashton Faulkner

Paolo Madeddu



Citation

Gu, Y., Avolio, E., Alvino, V. V., Thomas, A. C., Herman, A., Miller, P. J., …Madeddu, P. (in press). The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice. Cardiovascular Diabetology, 22(1), https://doi.org/10.1186/s12933-023-01955-9

Journal Article Type Article
Acceptance Date Aug 8, 2023
Online Publication Date Aug 17, 2023
Deposit Date Aug 21, 2023
Publicly Available Date Aug 23, 2023
Journal Cardiovascular Diabetology
Publisher BioMed Central
Peer Reviewed Peer Reviewed
Volume 22
Issue 1
DOI https://doi.org/10.1186/s12933-023-01955-9
Keywords Cardiology and Cardiovascular Medicine; Endocrinology, Diabetes and Metabolism
Additional Information Received: 5 June 2023; Accepted: 8 August 2023; First Online: 17 August 2023; : ; : Experimental procedures involving human patients were covered by ethical approval from Wales Rec 4 (REC reference number: 14/WA/1005) and in compliance with the “Declaration of Helsinki” principles. Patients gave written informed consent for participation in the study.; : Experimental procedures involving mice were approved by the British Home Office (PPL number PP1377882), the University of Bristol, and were compliant with the EU Directive 2010/63/EU and principles stated in the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996).; : Not Applicable.; : The authors declare no competing interests.

Files




You might also like



Downloadable Citations